NCT07212686View on ClinicalTrials.gov

Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2030

Conditions
Vasodilatory Shock
Interventions
DRUG

Angiotensin-II

Angiotensin-II will be given per the titration protocol.

Trial Locations (2)

11040

Cohen Children's Medical Center of Northwell Health, New Hyde Park

11101

Cohen Children's Medical Center, Queens

Sponsors
All Listed Sponsors
collaborator

Innoviva Specialty Therapeutics

INDUSTRY

lead

Todd Sweberg

OTHER

NCT07212686 - Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension | Biotech Hunter | Biotech Hunter